Skip to main content

Table 1 Risk factors involved in a published clinical risk score for prediction of TIC

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

Risk Factor Points
Adjuvant Therapy
 Anthracycline chemotherapy 2
 Non-anthracycline chemotherapy 2
 No identified chemotherapy 0
Age category, years
 67 to 74 0
 75 to 79 1
 80 to 94 2
Cardiovascular conditions and risk factors
 Coronary artery disease 2
 Atrial fibrillation/flutter 2
 Diabetes mellitus 1
 Hypertension 1
 Renal failure 2
  1. Low risk = 0–3 points, moderate risk = 3–4 points and high risk ≥6 points. Table modified from Ezaz et al., Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. JAHA 2014:3:e000472